0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018

      research-article
      , MPH 1 , 2 , , MD, MSc 3 , 4 , , PhD 5 , , PhD 1 ,
      JAMA Network Open
      American Medical Association

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          What was the excess mortality from respiratory syncytial virus (RSV) and influenza in the US from 1999 to 2018?

          Findings

          This cross-sectional study estimates a mean of 6549 underlying respiratory deaths associated with RSV each year (range, 5035-7645) and estimates a mean of 10 171 underlying respiratory deaths associated with influenza per year (range, 393 to 23 176), with greater interannual variation for influenza than for RSV. The highest mortality for both viruses was among individuals aged 65 years or older; RSV mortality was 5-fold higher than influenza mortality among children younger than 1 year.

          Meaning

          This study suggests that, despite changes in epidemiology, endemic respiratory viruses continue to have a significant death toll in the US, especially among infants and elderly individuals.

          Abstract

          Importance

          Respiratory syncytial virus (RSV) mortality estimates have not been updated since 2009, and no study has assessed changes in influenza mortality after the 2009 pandemic. Updated burden estimates are needed to characterize long-term changes in the epidemiology of these viruses.

          Objective

          To evaluate excess mortality from RSV and influenza in the US from 1999 to 2018.

          Design, Setting, and Participants

          This cross-sectional study used data from 50.3 million US death certificates from 1999 to 2018 to create age-specific linear regression models and assess weekly mortality fluctuations above a seasonal baseline associated with RSV and influenza. Statistical analysis was performed for 1043 weeks from January 3, 1999, to December 29, 2018.

          Main Outcomes and Measures

          Excess mortality associated with RSV and influenza estimated from the difference between observed and expected underlying respiratory mortality each season.

          Results

          There were 50.3 million death certificates (50.1% women and 49.9% men; mean [SD] age at death, 72.7 [18.6] years) included in this analysis, 1.0% for children younger than 1 year and 73.4% for adults aged 65 years or older. A mean of 6549 (95% CI, 6140-6958) underlying respiratory deaths were associated with RSV annually, including 96 (95% CI, 92-99) deaths among children younger than 1 year. For influenza, there were 10 171 (95% CI, 9652-10 691) underlying respiratory deaths per year, with 23 deaths (95% CI, 19-27) among children younger than 1 year. The highest mean mortality rate per 100 000 population for both viruses was among adults aged 65 years or older at 14.7 (95% CI, 13.8-15.5) for RSV and 20.5 (95% CI, 19.4-21.5) for influenza. A lower proportion of influenza deaths occurred among those aged 65 years or older compared with earlier estimates (75.1% [95% CI, 67.4%-82.8%]). Influenza mortality was highest among those aged 65 years or older in seasons when A/H3N2 predominated (18 739 [95% CI, 16 616-21 336] deaths in 2017-2018) and among those aged 5 to 49 years when A/H1N1pdm2009 predominated (1683 [95% CI, 1583-1787] deaths in 2013-2014). Results were sensitive to the choice of mortality outcome and method, with the broadest outcome associated with annual means of 23 352 (95% CI, 21 814-24 891) excess deaths for RSV and 27 171 (95% CI, 25 142-29 199) for influenza.

          Conclusions and Relevance

          This study suggests that RSV poses a greater risk than influenza to infants, while both are associated with substantial mortality among elderly individuals. Influenza has large interannual variability, affecting different age groups depending on the circulating virus. The emergence of the influenza A/H1N1pdm2009 pandemic virus in 2009 shifted mortality toward middle-aged adults, a trend still observed to date. This study’s estimates provide a benchmark to evaluate the mortality benefits associated with interventions against respiratory viruses, including new or improved immunization strategies.

          Abstract

          This cross-sectional study uses data from 50.3 million US death certificates to evaluate excess mortality from respiratory syncytial virus (RSV) and influenza from 1999 to 2018.

          Related collections

          Most cited references36

          • Record: found
          • Abstract: found
          • Article: not found

          Respiratory syncytial virus infection in elderly and high-risk adults.

          Respiratory syncytial virus (RSV) is an increasingly recognized cause of illness in adults. Data on the epidemiology and clinical effects in community-dwelling elderly persons and high-risk adults can help in assessing the need for vaccine development. During four consecutive winters, we evaluated all respiratory illnesses in prospective cohorts of healthy elderly patients (> or =65 years of age) and high-risk adults (those with chronic heart or lung disease) and in patients hospitalized with acute cardiopulmonary conditions. RSV infection and influenza A were diagnosed on the basis of culture, reverse-transcriptase polymerase chain reaction, and serologic studies. A total of 608 healthy elderly patients and 540 high-risk adults were enrolled in prospective surveillance, and 1388 hospitalized patients were enrolled. A total of 2514 illnesses were evaluated. RSV infection was identified in 102 patients in the prospective cohorts and 142 hospitalized patients, and influenza A was diagnosed in 44 patients in the prospective cohorts and 154 hospitalized patients. RSV infection developed annually in 3 to 7 percent of healthy elderly patients and in 4 to 10 percent of high-risk adults. Among healthy elderly patients, RSV infection generated fewer office visits than influenza; however, the use of health care services by high-risk adults was similar in the two groups. In the hospitalized cohort, RSV infection and influenza A resulted in similar lengths of stay, rates of use of intensive care (15 percent and 12 percent, respectively), and mortality (8 percent and 7 percent, respectively). On the basis of the diagnostic codes of the International Classification of Diseases, 9th Revision, Clinical Modification at discharge, RSV infection accounted for 10.6 percent of hospitalizations for pneumonia, 11.4 percent for chronic obstructive pulmonary disease, 5.4 percent for congestive heart failure, and 7.2 percent for asthma. RSV infection is an important illness in elderly and high-risk adults, with a disease burden similar to that of nonpandemic influenza A in a population in which the prevalence of vaccination for influenza is high. An effective RSV vaccine may offer benefits for these adults. Copyright 2005 Massachusetts Medical Society.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Efficacy of high-dose versus standard-dose influenza vaccine in older adults.

            As compared with a standard-dose vaccine, a high-dose, trivalent, inactivated influenza vaccine (IIV3-HD) improves antibody responses to influenza among adults 65 years of age or older. This study evaluated whether IIV3-HD also improves protection against laboratory-confirmed influenza illness.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Mortality associated with influenza and respiratory syncytial virus in the United States.

              Influenza and respiratory syncytial virus (RSV) cause substantial morbidity and mortality. Statistical methods used to estimate deaths in the United States attributable to influenza have not accounted for RSV circulation. To develop a statistical model using national mortality and viral surveillance data to estimate annual influenza- and RSV-associated deaths in the United States, by age group, virus, and influenza type and subtype. Age-specific Poisson regression models using national viral surveillance data for the 1976-1977 through 1998-1999 seasons were used to estimate influenza-associated deaths. Influenza- and RSV-associated deaths were simultaneously estimated for the 1990-1991 through 1998-1999 seasons. Attributable deaths for 3 categories: underlying pneumonia and influenza, underlying respiratory and circulatory, and all causes. Annual estimates of influenza-associated deaths increased significantly between the 1976-1977 and 1998-1999 seasons for all 3 death categories (P<.001 for each category). For the 1990-1991 through 1998-1999 seasons, the greatest mean numbers of deaths were associated with influenza A(H3N2) viruses, followed by RSV, influenza B, and influenza A(H1N1). Influenza viruses and RSV, respectively, were associated with annual means (SD) of 8097 (3084) and 2707 (196) underlying pneumonia and influenza deaths, 36 155 (11 055) and 11 321 (668) underlying respiratory and circulatory deaths, and 51 203 (15 081) and 17 358 (1086) all-cause deaths. For underlying respiratory and circulatory deaths, 90% of influenza- and 78% of RSV-associated deaths occurred among persons aged 65 years or older. Influenza was associated with more deaths than RSV in all age groups except for children younger than 1 year. On average, influenza was associated with 3 times as many deaths as RSV. Mortality associated with both influenza and RSV circulation disproportionately affects elderly persons. Influenza deaths have increased substantially in the last 2 decades, in part because of aging of the population, underscoring the need for better prevention measures, including more effective vaccines and vaccination programs for elderly persons.
                Bookmark

                Author and article information

                Journal
                JAMA Netw Open
                JAMA Netw Open
                JAMA Network Open
                American Medical Association
                2574-3805
                28 February 2022
                February 2022
                28 February 2022
                : 5
                : 2
                : e220527
                Affiliations
                [1 ]Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, Maryland
                [2 ]Brotman Baty Institute for Precision Medicine, University of Washington School of Medicine, Seattle
                [3 ]Department of Modeling, Epidemiology and Data Science, Sanofi Pasteur, Lyon, France
                [4 ]Foundation for Influenza Epidemiology, Fondation de France, Paris, France
                [5 ]Global RSV Medical Franchise Department, Sanofi Pasteur, Lyon, France
                Author notes
                Article Information
                Accepted for Publication: January 10, 2022.
                Published: February 28, 2022. doi:10.1001/jamanetworkopen.2022.0527
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Hansen CL et al. JAMA Network Open.
                Corresponding Author: Cécile Viboud, PhD, Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, 16 Center Dr, Bethesda, MD 20892 ( viboudc@ 123456mail.nih.gov ).
                Author Contributions: Ms Hansen and Dr Viboud had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: Chaves, Demont, Viboud.
                Acquisition, analysis, or interpretation of data: Hansen, Chaves, Viboud.
                Drafting of the manuscript: Hansen, Chaves, Viboud.
                Critical revision of the manuscript for important intellectual content: All authors.
                Statistical analysis: All authors.
                Obtained funding: Chaves.
                Supervision: Chaves, Viboud.
                Conflict of Interest Disclosures: Ms Hansen reported receiving personal contracting fees from Sanofi Pasteur during the conduct of the study and outside the submitted work. No other disclosures were reported.
                Funding/Support: Sanofi Pasteur provided partial support for Ms Hansen.
                Role of the Funder/Sponsor: Drs Chaves and Demont are employees of Sanofi Pasteur and were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
                Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US National Institutes of Health or Department of Health and Human Services.
                Additional Contributions: We thank the National Respiratory and Enteric Virus Surveillance System staff at the Centers for Disease Control and Prevention for providing respiratory syncytial virus surveillance data.
                Article
                zoi220034
                10.1001/jamanetworkopen.2022.0527
                8886548
                35226079
                a8627a91-4b87-47e3-9046-14c0c2ea018b
                Copyright 2022 Hansen CL et al. JAMA Network Open.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 11 October 2021
                : 10 January 2022
                Categories
                Research
                Original Investigation
                Online Only
                Public Health

                Comments

                Comment on this article